Abstract Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized
by memory loss and cognitive functions decline, is a leading cause for dementia and …

Alzheimer's disease (AD) is a devastating degenerative disorder of the brain for which there
is no cure or effective treatment. There is much evidence to suggest that β-amyloid protein …

Galanthamine, an acetylcholinesterase inhibitor marketed as a hydrobromide salt
(Razadyne®, Reminyl®) for the treatment of Alzheimer's disease (AD), is obtained from …

Alzheimer's disease (AD) continues to be a major global health challenge, and the recent
approval of Aduhelm and Leqembi has opened new avenues for its treatment. Small …

Alzheimer's disease (AD) is one of the most complicated neurodegenerative diseases, and
several hypotheses have been associated with its development and progression, such as …

The aggregation of β-amyloid peptides is associated to neurodegeneration in Alzheimer's
disease (AD) patients. Consequently, the inhibition of both oligomerization and fibrillation of …

Protein aggregation and amyloid fibrillation can lead to several serious human diseases and
protein drug ineffectiveness. The complexity and dynamics of protein folding present unique …

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering
from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or …

The number of patients diagnosed with Alzheimer's disease (AD) increases each year, and
there are currently few treatment strategies to decrease the symptoms of AD; furthermore …

The aggregation of Aβ is a crucial step in the etiology of Alzheimer's disease. Our previous
work showed that Aβ undergoes α-helix/β-sheet intermediate structures during the …